The US Food and Drug Administration (FDA) has approved Saniona's Investigational New Drug application. This allows the company to launch a phase 1 study to assess the safety, tolerability and pharmacokinetics of SAN2465 in healthy volunteers.
Using cognitive tests and EEG, the researchers will also study how the substance affects brain function and identify suitable doses for future patient studies.